Important Notice regarding Dextenza and Klarity-C

Posted in Latest News on October 15, 2019.

During the September 27, 2019 Board of Optometry meeting, the Board approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.

Important Note: At this time, Dextenza and Klarity-C cannot be prescribed by Certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on the board website and both may be prescribed by Certified Optometrists at that time.



More Latest News

Fourth Quarter Performance Report
September 2, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading


Website Server Maintenance Notice
July 5, 2022

Please be aware of website server maintenance for MQA Websites beginning Friday, July 8th at 5:00PM EST. Click here for more information. Continue reading